<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845013</url>
  </required_header>
  <id_info>
    <org_study_id>HIVPAP</org_study_id>
    <nct_id>NCT00845013</nct_id>
  </id_info>
  <brief_title>Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension</brief_title>
  <official_title>Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the epidemiology of pulmonary hypertension in&#xD;
      individuals with HIV infection and to investigate its pathogenesis. We propose to conduct a&#xD;
      prospective observational cohort study to determine the association between highly active&#xD;
      antiretroviral therapy (HAART) and viral suppression in HIV-infected patients who have been&#xD;
      identified to have pre-clinical pulmonary hypertension (Aim 1). In addition, we will&#xD;
      investigate the mechanistic role of the HIV-1 Nef protein and HHV-8 infection in the&#xD;
      development and progression of pulmonary hypertension in individuals with HIV (Aim 2). We&#xD;
      will also investigate endothelial function in HIV-infected patients with pulmonary&#xD;
      hypertension (Aim 3).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pulmonary artery pressure</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">365</enrollment>
  <condition>HIV Infection</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Endothelial Function</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV Infection</arm_group_label>
    <description>HIV-infected individuals with the clinical diagnosis of pulmonary hypertension or HIV-infected individuals who have mildly elevated pulmonary arterial pressures</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, PBMCS, BAL&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV infected individiuals with the clinical diagnosis of pulmonary hypertension or who have&#xD;
        mildly elevated pulmonary arterial pressures&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Infection with HIV greater than 6 months in duration&#xD;
&#xD;
          2. Right heart catheterization showing PASP &gt; 30mm Hg&#xD;
&#xD;
          3. Ability to provide reliable history of HIV medications or has received the majority of&#xD;
             medical care from San Francisco General Hospital with available records of medical&#xD;
             treatment.&#xD;
&#xD;
          4. Ability to participate in follow-up for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known significant cardiovascular disease, including clinically significant valvular&#xD;
             heart disease, congenital heart disease, current or prior symptomatic coronary&#xD;
             disease, or known cardiomyopathy.&#xD;
&#xD;
          2. Any known pulmonary disease that could potentially cause pulmonary hypertension.&#xD;
&#xD;
          3. A pO2 by pulse oximetry below 90% on room air.&#xD;
&#xD;
          4. Obstructive sleep apnea.&#xD;
&#xD;
          5. Known collagen vascular disease.&#xD;
&#xD;
          6. History of anorexigen use&#xD;
&#xD;
               -  7. Age less than 18 years old.&#xD;
&#xD;
               -  8. Other co-morbidities for which the investigators, in conjunction with the&#xD;
                  primary care provider, believe render the participant with an expected survival&#xD;
                  of 6 months or less.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priscilla Hsue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>endothelial function</keyword>
  <keyword>antiretroviral medication</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

